According to Future Market Insights, the oncolytic adenovirus market size is anticipated to expand at a rate of 7.5% CAGR between 2023 and 2033. It is anticipated that the oncolytic adenovirus market would reach a valuation of US$ 250 billion by 2033. The market’s expansion may be ascribed to major manufacturers investing more in oncolytic adenovirus research and drug development.
The COVID-19 pandemic affected the development of the oncolytic adenovirus owing to the disruption in the research and development of medication. Lack of funds and access to resources to develop and innovate therapies is affecting the growth of the market. On the other hand, post-pandemic, the increasing use of technology in the formation of therapies is positively influencing the growth of the oncolytic adenovirus market.
Get a Sample Copy of the Report:
https://www.futuremarketinsights.com/reports/sample/rep-gb-16235
The prevalence of people being affected by cancer in North America and Asia Pacific is a key driver for the growth of the oncolytic adenovirus market. Increasing healthcare expenditure and integration of technology to understand the nature and effect of oncolytic adenovirus is propelling the growth of the overall market. In the upcoming forecast period, funding by government and non-government organizations is expected to drive the overall growth of the market.
Key Takeaways :
- The oncolytic adenovirus market is expected to possess 7.5% CAGR in the forecast period 2023-2033
- By application, lung cancer is expected to possess 35% market share for oncolytic adenovirus in 2023.
- North America is expected to possess 43% market share for Oncolytic adenovirus market in 2023.
- Asia Pacific oncolytic adenovirus market size is expected to possess 39% market share in 2023.
“Growing prevalence of cancer amongst all age groups along with technological integration to create therapeutic medication is creating lucrative opportunities for oncolytic adenovirus market.” states a FMI analyst
Competitive Landscape
Key players in the oncolytic adenovirus market are Amgen, Sorrento Therapeutics, Transgene SA, Oncolys BioPharma, Targovax, Lokon Pharma, Vyriad, TILT Biotherapeutics, CG Oncology Inc, VCNBiosciences, DNAtrix, Replimune Group Inc
- Lokon Pharma AB is a Swedish biotech company developing the LOAd platform of oncolytic adenoviruses genetically engineered to express immunostimulatory genes in malignant tumors and tumor stroma.
- TILT Biotherapeutic’s head of R&D Riikka Havunen was awarded oral presentation “Oncolytic adenoviruses armed with tumor necrosis factor alpha and interleukin-2 enable treatment of solid tumors with T cell therapies” at the 16th Cancer Immunotherapy Annual Meeting in Mainz, Germany in May 2018.
More Valuable Insights
Future Market Insights, in its new offering, presents an unbiased analysis of the global Oncolytic adenovirus market, presenting historical analysis from 2017 to 2022 and forecast statistics for the period of 2023-2033.
The study reveals essential insights on the basis of Type (HSV-based Oncolytic Viruses, Adenoviruses-based Oncolytic Viruses, Others), Application (Melanoma, Prostate Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer, Others), regions (North America, Latin America, Europe, Asia Pacific, and Middle East & Africa).
Unlock exclusive insights with our expert analysts:
https://www.futuremarketinsights.com/ask-question/rep-gb-16235
Key Segments :
Type:
- HSV-based Oncolytic Viruses
- Adenoviruses-based Oncolytic Viruses
- Others
Application:
- Melanoma
- Prostate Cancer
- Breast Cancer
- Ovarian Cancer
- Lung Cancer
- Others
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
